| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NLS1878AF405 | |||
| Alexa Fluor 488 | NLS1878AF488 | |||
| Alexa Fluor 647 | NLS1878AF647 | |||
| Alexa Fluor 700 | NLS1878AF700 | |||
| Biotin | NLS1878B | |||
| DyLight 405 | NLS1878V | |||
| DyLight 488 | NLS1878G | |||
| DyLight 550 | NLS1878R | |||
| DyLight 650 | NLS1878C | |||
| FITC | NLS1878F | |||
| HRP | NLS1878H | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-59787SS | |||
![Detection of Human and Mouse Histone H2AX [p Ser139] by Western Blot. Samples: Nuclear extract (50 ug) from human HEK293, human melanoma (G361), mouse wildtype embryonic fibroblasts (+/+) or mouse H2AX knockout embryonic fibroblasts (-/-). Antibody: Affinity purified rabbit Histone H2AX [p Ser139] antibody NB100-384 used at 0.1 ug/ml. Detection: Chemiluminescence with 30 second exposure. (NCS, neocarzinostatin - 200 ng/ml, 30 min). Bands appear at an observed molecular weight of ~15 kDa.](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Western-Blot-NB100-384-img0012.jpg "<b>Genetic Strategies Validation. </b>Detection of Human and Mouse Histone H2AX [p Ser139] by Western Blot. Samples: Nuclear extract (50 ug) from human HEK293, human melanoma (G361), mouse wildtype embryonic fibroblasts (+/+) or mouse H2AX knockout embryonic fibroblasts (-/-). Antibody: Affinity purified rabbit Histone H2AX [p Ser139] antibody NB100-384 used at 0.1 ug/ml. Detection: Chemiluminescence with 30 second exposure. (NCS, neocarzinostatin - 200 ng/ml, 30 min). Bands appear at an observed molecular weight of ~15 kDa.")
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Samples: Neocarzinostatin treated asynchronous HeLa cells (left) and untreated asynchronous HeLa cells (right) . Antibody: Affinity purified rabbit Histone H2AX [p Ser139] used at a dilution of 1:5,000 (0.2ug/ml). Detection: Red fluorescent Anti-rabbit IgG-DyLight 594 used at a dilution of 1:100.](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-384-img0009.jpg)
![Simple Western lane view shows a specific band for Histone H2AX [p Ser139] in 0.2 mg/ml of Jurkat lysate(s). This experiment was performed under reducing conditions using the 12 - 230 kDa separation system.](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Simple-Western-NB100-384-img0014.jpg)
![Immunostaining of Histone H2AX [p Ser139] WT1 and 5mC in patients with IgA nephropathy and controls. Examples of PAS staining and immunostaining with Histone H2AX [p Ser139] (green) and WT1 (red), pATM and 5mC in glomeruli of IgA nephropathy and controls. A kidney sample of a 65-year-old male of IgA nephropathy without podocytopathic features. Arrows indicate Histone H2AX [p Ser139] and WT1 double-positive cells. Scale bars: 50um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-57140-0) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-384-img0022.jpg)
![<b>Biological Strategies Validation. </b>Samples: Nuclear extract from HeLa cells treated with 100 uM EPE for 4 hours (+) or mock treated (-). Antibody: Affinity purified rabbit Histone H2AX [p Ser139] antibody used at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes. Band appears at an observed molecular weight of ~17 kDa.](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Western-Blot-NB100-384-img0016.jpg)
![<b>Biological Strategies Validation. </b>Detection of human Histone H2AX [p Ser139] by western blot. Samples: Whole cell lysate (50 ug) from Jurkat cells treated with 100 uM EPE for 4 hours (+) or mock treated (-). Antibody: Affinity purified rabbit Histone H2AX [p Ser139] antibody NB100-384 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 seconds. Band appears at an observed molecular weight of ~18 kDa.](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Western-Blot-NB100-384-img0019.jpg)
![FFPE section of mouse CT26 colon carcinoma. Antibody: Affinity purified rabbi Histone H2AX [p Ser139] antibody used at a dilution of 1:1,000 (1 ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Immunohistochemistry-Paraffin-NB100-384-img0026.jpg)
![Analysis of Histone H2AX [p Ser139] in EPE Treated Jurkat Cells. Cells were treated for 3 hrs in 5ug/ml etoposide, fixed in 1.5% PFA, and permeabilized in 90% Methanol. 1 million cells were stained with 0.5 ug anti-KLH or anti-H2AX NB100-384 and secondary FITC-conjugated goat anti-rabbit (in a 150ul reaction). Black- etosposide treated, anti-KLH; Red- untreated, anti-Histone H2AX [p Ser139]; Blue- etoposide treated , anti-Histone H2AX [p Ser139].](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Flow-Cytometry-NB100-384-img0008.jpg)
![FFPE section of human ovarian carcinoma. Antibody: Affinity purified rabbit Histone H2AX [p Ser139] antibody used at a dilution of 1:5,000 (0.2 ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Immunohistochemistry-Paraffin-NB100-384-img0025.jpg)
![Electropherogram image(s) of corresponding Simple Western lane view. Histone H2AX [p Ser139] antibody was used at 5 ug/ml dilution on Jurkat lysate(s).](http://images.novusbio.com/fullsize/gamma-H2AX-[p-Ser139]-Antibody-Simple-Western-NB100-384-img0015.jpg)
![Immunohistochemistry: Rabbit Polyclonal Histone H2AX [p Ser139] Antibody - Histone H2AX Antibody on mouse cancer tissue. H2AX (Gray) and H2BGFP(Green). Primary antibody dilution: 1:1000 in a 10um slice.](http://images.novusbio.com/fullsize/antibody/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-immunohistochemistry-16102023102936..png)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - ATM & NF-kappa B activation are downregulated in Ercc1-/ delta mice heterozygous for Atm. (A) Livers were collected at 12 weeks of age from WT, Ercc1-/ delta & Ercc1-/ delta Atm+/- mic (n=3 per genotype) & lysates analyzed by western blot for activation of ATM & its downstream effectors. (B) Same liver lysates were used to measure phosphorylation of p65 & I kappa B alpha . (C) Western blot analysis of livers from 16-week-old WT, Ercc1-/ delta & Ercc1-/ delta Atm+/-mice (n=3 per genotype) probed for activation of ATM. GAPDH was used as a loading control. (D) Same liver lysates used to measure activation of NF-kappa B. (E) Fourteen-week-old livers from Ercc1-/ delta & Ercc1-/ delta p65+/- mice (n=3 per genotype) were analyzed by western blot for activation of ATM (F) & NF-kappa B. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32201398), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415371991.jpg)
![Immunocytochemistry/ Immunofluorescence: Histone H2AX [p Ser139] Antibody [NB100-384] - Immunostaining of gamma H2AX, WT1 & 5mC in patients with IgA nephropathy & controls. Examples of PAS staining & immunostaining with gamma H2AX (green) & WT1 (red), pATM & 5mC in glomeruli of IgA nephropathy & controls. (A) A control kidney sample of 44-year-old female, (B) 65-year-old male of IgA nephropathy without podocytopathic features & (C) 55-year-old male of IgA nephropathy with podocytopathic features. Arrows indicate gamma H2AX & WT1 double-positive cells. Scale bars: 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31937846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-3102024153972.jpg)
![Immunocytochemistry/ Immunofluorescence: Histone H2AX [p Ser139] Antibody [NB100-384] - UHRF1 deficiency resulted in impaired meiotic recombination & defective pachynema.a Double immunofluorescence of SYCP3 (green) & DMC1 (red) in testicular spread preparations. b, c The number of DMC1 foci in zygotene stage (b) & pachytene stage (c). d Immunostaining for SYCP3 (red) & gamma H2AX (green). e The percentage of abnormal gamma H2AX foci in the pachytene stage. f Immunostaining for SYCP3 (red) & MLH1 (green). g The number of MLH1 foci in pachynema. h Immunostaining for SYCP3 (red) & H1t (green). i The percentage of spermatocytes with H1T staining. ***p ≤ 0.001; *p ≤ 0.05. Scale bar, 5 μm in a, d, f, h. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32081844), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415384166.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - mTORC1/2 activity prevents Cisplatin-induced cell death in MCF-10A cells. (A) Western blot displaying effects on mTOR signaling during a dose escalation of PP242 treatment in MCF-10A cells; (B) Western blot displaying effects of mTOR signaling on a dose escalation of cisplatin treatment in MCF-10A cells; (C) Western blot displaying effects on mTOR signaling & cell death during non-treated, Cisplatin, PP242, & Cisplatin + PP242-treated MCF-10A cells. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31771139), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415304284.jpg)
![Immunocytochemistry/ Immunofluorescence: Histone H2AX [p Ser139] Antibody [NB100-384] - Immunostaining of gamma H2AX, WT1 & 5mC in patients with IgA nephropathy & controls. Examples of PAS staining & immunostaining with gamma H2AX (green) & WT1 (red), pATM & 5mC in glomeruli of IgA nephropathy & controls. (A) A control kidney sample of 44-year-old female, (B) 65-year-old male of IgA nephropathy without podocytopathic features & (C) 55-year-old male of IgA nephropathy with podocytopathic features. Arrows indicate gamma H2AX & WT1 double-positive cells. Scale bars: 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31937846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415371942.jpg)
![Immunocytochemistry/ Immunofluorescence: Histone H2AX [p Ser139] Antibody [NB100-384] - Immunostaining of gamma H2AX, WT1 & 5mC in patients with IgA nephropathy & controls. Examples of PAS staining & immunostaining with gamma H2AX (green) & WT1 (red), pATM & 5mC in glomeruli of IgA nephropathy & controls. (A) A control kidney sample of 44-year-old female, (B) 65-year-old male of IgA nephropathy without podocytopathic features & (C) 55-year-old male of IgA nephropathy with podocytopathic features. Arrows indicate gamma H2AX & WT1 double-positive cells. Scale bars: 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31937846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-31020241534358.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - ATM & NF-kappa B activation are downregulated in Ercc1-/ delta mice heterozygous for Atm. (A) Livers were collected at 12 weeks of age from WT, Ercc1-/ delta & Ercc1-/ delta Atm+/- mic (n=3 per genotype) & lysates analyzed by western blot for activation of ATM & its downstream effectors. (B) Same liver lysates were used to measure phosphorylation of p65 & I kappa B alpha . (C) Western blot analysis of livers from 16-week-old WT, Ercc1-/ delta & Ercc1-/ delta Atm+/-mice (n=3 per genotype) probed for activation of ATM. GAPDH was used as a loading control. (D) Same liver lysates used to measure activation of NF-kappa B. (E) Fourteen-week-old livers from Ercc1-/ delta & Ercc1-/ delta p65+/- mice (n=3 per genotype) were analyzed by western blot for activation of ATM (F) & NF-kappa B. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32201398), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-3102024153565.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - Pharmacologic inhibition of ATM rescues oxidative stress-induced senescence by suppressing ATM- & NEMO-mediated NF-kappa B activation. (A) Representative images of primary WT & Ercc1-/- MEFs were induced to undergo senescence by serial passaging at 20% oxygen. At passage 5, MEFs were grown in the presence or absence of KU-55933 (10 μM) for 72 hrs. Senescence was determined by SA-beta gal staining. Images were obtained at the magnification of 10x. (B) Quantitation of the percent SA-beta gal positive cells. Graph represents the mean +/- s.e.m. of three independent experiments. Student’s t-test, ***p <0.001, ****p <0.0001. (C) Passage 5 Ercc1-/- MEFs treated with vehicle or KU-55933 (10 μM) for 72 hours were collected & levels of p21 & p16INK4a were determined by western blotting. (D) Passage 5 Ercc1-/- MEFs were treated with KU-55933 (10 μM) for 72 hours & whole cell lysate (CL) & nuclear extracts (NE) were analyzed by immunoblotting for expression of proteins involved in the DNA damage response. (E) Whole cell lysate (CL) & nuclear extract (NE) were extracted from Ercc1-/- MEFs treated with 10 μM of KU-55933 for analysis of nuclear NEMO & p65. GAPDH was used as a loading control of total proteins & LaminA/C as a loading control of nuclear protein. (F) Passage 5 WT & Ercc1-/- MEFs transfected with a NF-kappa B-luciferase reporter construct were cultured in the presence or absence of KU-55933 (10 μM) & were collected for luciferase assays after 72 hours. (G) qRT-PCR analysis of mRNA expression in passage 5 WT & Ercc1-/- MEFs treated with or without of KU-55933 (10 μM) for 72 hrs. P values were determined using a Student’s t-test. *p<0.05, **p<0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32201398), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415525231.jpg)
![Immunohistochemistry: Histone H2AX [p Ser139] Antibody [NB100-384] - Orally administered lemongrass & white tea extract reduce tumor size in lymphoma xenograft model in immunocompromised miceImmunocompromised mice were subcutaneously injected with cancerous cells & tumors were allowed to establish. Treatments occurred every other day & the studied compound or the equivalent vehicle control administered orally for three weeks. (A, B) The tumors were photographed before & after extraction from the animals. (C) Tumor volume & mass were measured two times per week. (D) Immunohistochemistry analysis of sectioned tumor tissues from the lymphoma study. Each section was subjected to the specified antibody followed by a biotinylated secondary antibody. Detection was done using a DAB Peroxidase HRP Substrate Kit (brown) followed by Hematoxylin counterstaining (purple). Images were obtained using inverted bright field microscopy. Sectioning results are representative of three individual tumors. Scale bar is 50 microns. Statistical analysis using One-Way ANOVA. *p < 0.05 vs tumor volume of the control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202416572.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - CPT induces transcription- & proteasome-dependent apoptosis in quiescent WI38 hTERT cells. (A & B) Serum-starved cells were treated with DMSO or FLV (1 μM) for 1 h before the addition of DMSO or CPT (25 μM) for 16 & 24 h. (A) Percentages of cells that remained attached to culture flasks (means ± SD of quadruplicates). (B) Cell survival was analyzed by a CellTiter-Blue assay (means ± SD of triplicates). (C–G) Western blot of the indicated proteins in serum-starved cells treated for 1 h with DMSO or with FLV (1 μM) (C), lactacystin (10 μM) (D), veliparib (5 μM) or olaparib (10 μM) (E), ATMi (10 μM) (F) or DNA-PKi (10 μM) (G) before the addition of DMSO (‘-’, 24 h in panels C & F) or CPT (25 μM) for the indicated times. Data shown are representatives from two to three experiments. PARPCL: cleaved PARP. H2AX & alpha Tubulin were the loading controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26578593), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415533820.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - Inhibition of DNA-PK prevents monoubiquitination of H2AX & H2A in CPT-treated quiescent WI38 hTERT cells. (A–E) Serum-starved cells were treated with DMSO or DNA-PKi (10 μM) for 1 h before the addition of DMSO (untreated) or CPT (25 μM) for 1 h. (A) Western blot of gamma H2AX. +Ub1 indicates gamma H2AX monoubiquitinated. The top panel shows quantification of Ub1-gamma H2AX normalized to alpha Tubulin (means ± SEM, n = 4). **P < 0.01. (B & C) Cells were pre-extracted with CSK buffer before co-staining for Ub-H2A (red) & 53BP1 phosphorylated on S1778 (p53BP1) (green). (B) Representative pictures. Images were merged to determine colocalization (yellow). The large Ub-H2AX focus at the periphery of the nuclei of untreated & CPT-treated cells may marks the inactive X chromosome as reported (91). (C) Percentages of nuclei with at least 5 Ub-H2A foci (means ± SEM, n = 3, 100 nuclei were analyzed for each treatment in each experiment). ***P < 0.001. (D & E) Cells were co-stained for ubiquitinated proteins (FK2, red) & gamma H2AX (green). (D) Representative pictures. Images were merged to determine colocalization (yellow). (E) Number of FK2 foci per nucleus from one representative experiment (76–111 nuclei were analyzed for each treatment) out of three. ****P < 0.0001. In the microscopic images, nuclear contours, identified by DAPI staining (blue in the merge images at bottom), are indicated by dashed lines. Bars: 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26578593), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415541922.jpg)
![Immunocytochemistry/ Immunofluorescence: Histone H2AX [p Ser139] Antibody [NB100-384] - The production of DSBs depends on Top1 degradation in CPT-treated quiescent cells. (A–C) Serum-starved WI38 hTERT cells were co-transfected with siRNAs against cullin 3 & cullin 4B or against a control sequence & then treated with DMSO (−CPT) or 25 μM CPT (+CPT) for 1 h. (A & B) Western blotting of the indicated proteins. alpha Tubulin: loading control. (C) Number of gamma H2AX foci per nucleus from one representative experiment (246–348 nuclei were analyzed for each treatment) out of three. ***P < 0.001. (D & E) Serum-starved WI38 hTERT cells were treated with DMSO or MG132 (50 μM) for 1 h before exposure to 0.8 Gy IR. One hour post-irradiation, cells were co-stained for gamma H2AX (green) & 53BP1 (red). (D) Representative pictures. (E) Number of gamma H2AX foci per nucleus from one representative experiment (162–180 nuclei were analyzed for each treatment) out of three. Ns: not significant. (F & G) U2OS EV28 cells were treated with DMSO or MG132 (10 μM) for 1 h before the addition of ethanol (untreated) or 300 nM 4-hydroxitamoxifen (4OHT) for 4 h to express AsiSI in the nucleus (42). (F) Representative pictures of cells co-stained for gamma H2AX (green) & 53BP1 (red). (G) ChIP analysis using an anti-gamma H2AX antibody (black) or a non-immune antibody (IgG, gray). Enrichment was assessed by QPCR amplification using primers proximal to two AsiSI sites located inside two genes (Gene I: SFRS6, Gene II: CCD47) & primers distal to an AsiSI site (Control). Enrichment was normalized to the maximum recovery for each experiment (means ± SEM, n = 3). Ns: not significant; *P < 0.05. In the microscopic images, nuclear contours, identified by DAPI staining (not shown), are indicated by dashed lines. Bars: 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26578593), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415525243.jpg)
![Immunocytochemistry/ Immunofluorescence: Histone H2AX [p Ser139] Antibody [NB100-384] - Inhibition of DNA-PK prevents monoubiquitination of H2AX & H2A in CPT-treated quiescent WI38 hTERT cells. (A–E) Serum-starved cells were treated with DMSO or DNA-PKi (10 μM) for 1 h before the addition of DMSO (untreated) or CPT (25 μM) for 1 h. (A) Western blot of gamma H2AX. +Ub1 indicates gamma H2AX monoubiquitinated. The top panel shows quantification of Ub1-gamma H2AX normalized to alpha Tubulin (means ± SEM, n = 4). **P < 0.01. (B & C) Cells were pre-extracted with CSK buffer before co-staining for Ub-H2A (red) & 53BP1 phosphorylated on S1778 (p53BP1) (green). (B) Representative pictures. Images were merged to determine colocalization (yellow). The large Ub-H2AX focus at the periphery of the nuclei of untreated & CPT-treated cells may marks the inactive X chromosome as reported (91). (C) Percentages of nuclei with at least 5 Ub-H2A foci (means ± SEM, n = 3, 100 nuclei were analyzed for each treatment in each experiment). ***P < 0.001. (D & E) Cells were co-stained for ubiquitinated proteins (FK2, red) & gamma H2AX (green). (D) Representative pictures. Images were merged to determine colocalization (yellow). (E) Number of FK2 foci per nucleus from one representative experiment (76–111 nuclei were analyzed for each treatment) out of three. ****P < 0.0001. In the microscopic images, nuclear contours, identified by DAPI staining (blue in the merge images at bottom), are indicated by dashed lines. Bars: 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26578593), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-31020241682137.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - DDR & NF-kappa B are activated concomitantly in senescent MEFs & aged tissues. (A) Immunoblot detection of p-p65 & total p65 in liver tissue from 16-week-old WT (n=3) & Ercc1-/ delta (n=3) mice. (B) Immunoblot detection of phosphorylation of ATM & downstream targets gamma H2AX & p21 in liver from 16-week-old WT & Ercc1-/ delta mice. (C) Immunoblot detection of phosphorylation of NF-kappa B & I kappa B alpha in liver lysates from 3, 12 & 24 month-old WT mice. n=3 mice per group. (D) Immunoblot detection of p-ATM, ATM & p21 in the same liver lysates. (E) Immunoblot detection of DDR effectors in nuclear extracts from passage 5 WT & Ercc1-/- MEFs, grown at 20% oxygen. (F) Level of NF-kappa B activation is higher in Ercc1-/- MEFs compared to WT MEFs at passage 5, as measured by Immunoblot detection of p-p65 & total p65 in WT & Ercc1-/- MEFs at passage 5 after culturing in 20% oxygen. (G) Representative images of immunofluorescent detection of p65 & NEMO in passage 4 WT & Ercc1-/- MEFs grown at 20% oxygen. Blue: DAPI staining; Green: p65 (top panel) or NEMO (bottom panel). Images were taken at the magnification of 60x. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32201398), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-3102024165718.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - DDR & NF-kappa B are activated concomitantly in senescent MEFs & aged tissues. (A) Immunoblot detection of p-p65 & total p65 in liver tissue from 16-week-old WT (n=3) & Ercc1-/ delta (n=3) mice. (B) Immunoblot detection of phosphorylation of ATM & downstream targets gamma H2AX & p21 in liver from 16-week-old WT & Ercc1-/ delta mice. (C) Immunoblot detection of phosphorylation of NF-kappa B & I kappa B alpha in liver lysates from 3, 12 & 24 month-old WT mice. n=3 mice per group. (D) Immunoblot detection of p-ATM, ATM & p21 in the same liver lysates. (E) Immunoblot detection of DDR effectors in nuclear extracts from passage 5 WT & Ercc1-/- MEFs, grown at 20% oxygen. (F) Level of NF-kappa B activation is higher in Ercc1-/- MEFs compared to WT MEFs at passage 5, as measured by Immunoblot detection of p-p65 & total p65 in WT & Ercc1-/- MEFs at passage 5 after culturing in 20% oxygen. (G) Representative images of immunofluorescent detection of p65 & NEMO in passage 4 WT & Ercc1-/- MEFs grown at 20% oxygen. Blue: DAPI staining; Green: p65 (top panel) or NEMO (bottom panel). Images were taken at the magnification of 60x. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32201398), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-31020241682193.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - Induction of ubiquitin/proteasome-dependent DSBs in CPT-treated quiescent WI38 hTERT cells. (A–F) Serum-starved cells were treated with DMSO (1 h) or with MG132 (50 μM, 1 h), lactacystin (10 μM, 1 h), bortezomib (1 μM, 4 h), G5 (1.5 μM, 0.5 h) or Pyr-41 (9 μM, 0.5 h) before the addition of DMSO (untreated) or 25 μM CPT for 1 h & then co-stained for gamma H2AX (green) & 53BP1 (red) or analyzed by Western blot. ‘-’ in panels C & F means cells treated with DMSO. (A & D) Representative pictures. Nuclear contours, identified by DAPI staining (not shown), are indicated by dashed lines. Bars: 10 μm. (B & E) Number of gamma H2AX foci per nucleus from two independent experiments (147–153 nuclei were analyzed for each treatment). ****P < 0.0001. (C & F) Western blot of gamma H2AX. alpha Tubulin: loading control. Dashed lines indicate that intervening wells have been spliced out. The top panels show quantification of gamma H2AX normalized to alpha Tubulin (means ± SEM, n = 4 in panel C, n = 3 in panel F). ***P < 0.001; **P < 0.01. (G & H) Detection of DSBs by neutral Comet assays in serum-starved cells treated with DMSO or MG132 (25 μM) for 1 h before the addition of DMSO (untreated) or CPT for 1 h (7.5 μM for experiments (Exp) I & II; 5 & 7.5 μM for Exp III). (G) Representative pictures of nuclei from Exp I. (H) Quantification of neutral Comet tail moments for three independent experiments (95–133 nuclei were analyzed for each treatment in each experiment). ***P < 0.001; ****P < 0.0001. The untreated & CPT data from Exp I are from the same experiment as that of Supplementary Figure S3D. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26578593), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-310202415541946.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - Curcumin Analogs Induce Apoptosis in Cancerous Cells by Several Pathways. (a) E6-1 (Jurkat), dominant negative FADD (dnFADD) Jurkat, & overexpressing BCL-2 Jurkat were treated for 48 hours then stained for Annexin V & PI (b) E6-1 cells were plated & treated with or without the broad spectrum caspase inhibitor ZVAD(oMe)-FMK for 48 hours. Cells were stained for Annexin V & PI. Results were obtained using image-based cytometry with the Y-axis representative of percent of cells positive for Annexin V (green), PI (red), Annexin V & PI (yellow), or negative for both Annexin V & PI (blue). Values are expressed as a mean ± SD from three independent experiments. (c) E6-1 cells were treated for 24 hours with or without the broad spectrum caspase inhibitor ZVAD(oMe)-FMK & the studied compounds, lysed & subjected to Western blot analysis. (d) NHF & NCM460 cells were treated for 48 hours & 72 hours respectively, lysed & subjected to Western blot analysis. Bands were visualized with a chemiluminescence reagent. Images are representative of three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison. *p < 0.05 vs % viable of Control (DMSO); #p < 0.05 vs % viable cells for groups without Z-VAD(oMe)FMK. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28439094), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-31020241612653.jpg)
![Western Blot: Histone H2AX [p Ser139] Antibody [NB100-384] - Curcumin Analogs Induce Apoptosis in Cancerous Cells by Several Pathways. (a) E6-1 (Jurkat), dominant negative FADD (dnFADD) Jurkat, & overexpressing BCL-2 Jurkat were treated for 48 hours then stained for Annexin V & PI (b) E6-1 cells were plated & treated with or without the broad spectrum caspase inhibitor ZVAD(oMe)-FMK for 48 hours. Cells were stained for Annexin V & PI. Results were obtained using image-based cytometry with the Y-axis representative of percent of cells positive for Annexin V (green), PI (red), Annexin V & PI (yellow), or negative for both Annexin V & PI (blue). Values are expressed as a mean ± SD from three independent experiments. (c) E6-1 cells were treated for 24 hours with or without the broad spectrum caspase inhibitor ZVAD(oMe)-FMK & the studied compounds, lysed & subjected to Western blot analysis. (d) NHF & NCM460 cells were treated for 48 hours & 72 hours respectively, lysed & subjected to Western blot analysis. Bands were visualized with a chemiluminescence reagent. Images are representative of three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison. *p < 0.05 vs % viable of Control (DMSO); #p < 0.05 vs % viable cells for groups without Z-VAD(oMe)FMK. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28439094), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-384_rabbit-polyclonal-histone-h2ax-p-ser139-antibody-31020241683932.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Samples: Whole cell lysate (15 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-ZEB1 antibody (NBP1-05987) used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Western-Blot-NBP1-05987-img0017.jpg "Western Blot: ZEB1 Antibody [NBP1-05987] - Samples: Whole cell lysate (15 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-ZEB1 antibody (NBP1-05987) used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.")
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti-ZEB1 (NBP1-05987) used at a dilution of 1:1000 (0.2 ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0019.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Analysis of ZEB1 in transfected and native mouse cell lysate. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Western-Blot-NBP1-05987-img0003.jpg)
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Analysis of ZEB1 in human liver and spleen tissues. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0004.jpg)
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti-ZEB1 (NBP1-05987) used at a dilution of 1:1000 (0.2 ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0018.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: ZEB1 Antibody [NBP1-05987] - Detection of human ZEB1 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-ZEB1 antibody NBP1-05987 used for IP at 3 ug per reaction. ZEB1 was also immunoprecipitated by another rabbit anti-ZEB1 antibody. For blotting immunoprecipitated ZEB1, NBP1-05987 was used at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunoprecipitation-NBP1-05987-img0013.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415382430.jpg)
![Immunohistochemistry: ZEB1 Antibody [NBP1-05987] - Immunohistochemical staining results of EMT regulators in HG‐PanIN: SNAIL, SLUG, TWIST1, & ZEB1. We categorized & defined three grades: grade 0, <10% positive staining; grade 1, 10%‐50% positive; grade 2, 50%< positive Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30791220), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415291996.jpg)
![Immunocytochemistry/ Immunofluorescence: ZEB1 Antibody [NBP1-05987] - Location of Zeb1 proteins in mEC lines (mESC, mEB, GC1, & P19). Immunofluorescence analysis was used to determine localization of Zeb1 in mESC, mEB, GC1, & P19 using a Zeb1 antibody (red). Cell nuclei were labeled with Hoechst 33342 (blue). The scale for the measurement bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241539712.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241529198.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415304286.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Zeb1 expression in mESCs, mEB, GC1, & P19. (a) Zeb1 mRNA expression detected by real-time qPCR in mESC, mEB, GC1, & P19 (P < 0.001, data presented as mean value ± SD). (b) Zeb1 protein expression examined by western blot in mESC, mEB, GC1, & P19. Each experiment was performed in triplicate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415304288.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241528450.jpg)
![Immunocytochemistry/ Immunofluorescence: ZEB1 Antibody [NBP1-05987] - Correlation of the expression of ZEB1 & IL‐6 & other cytokines in various cancers. (A) Correlation analysis of the expression of ZEB1 & cytokines in breast cancer cell lines using data obtained from the Cancer Cell Line Encyclopedia (CCLE). Breast cancer cell lines were selected for the analysis, & each dot represents a cell line. Affymetrix microarray probe IDs for IL6 & IL8 are shown after the gene symbols on the y‐axis. RMA, robust multiarray average. (B) Representative results obtained from the tissue array analysis in Fig. S3. The top panel shows a case that was positive for both nuclear ZEB1 staining (green) & whole‐cell IL‐6 staining (red); scores = 4. The bottom panel shows a case that was negative for both ZEB1 & IL‐6; scores = 1. The samples were counterstained with DAPI to show cell density in the spot. Original magnification: 20 ×. (C) Kaplan–Meier survival curves of breast & lung cancer patients obtained from a public meta‐analysis database & Kaplan–Meier plotter (Gyorffy et al., 2010, 2013). The probability of overall survival of patients as split by median IL6 & IL8 expression is shown. Red: IL6 & IL8 high expression group; black: IL6 & IL8 low expression group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28618162), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616091.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - SU5402, FGFR1 inhibitor, affects the EMT transcription factors.(A, B) ERK1/2 phosphorylation (p-ERK1/2) determined by immunoblotting in HSC-4 & OTC-04 treated for 30 min w/ 30 ng/ml FGF2 or 30 ng/ml FGF7 in presence of 10% FBS (A) & in TSU & HOC313 cells treated for 1 h w/ 30 ng/ml FGF2 or 30 μM SU5402 in absence of FBS (B). F2, FGF2; F7, FGF7; SU, SU5402. (C) We have previously reported that, after treatment w/ TGF-beta , NMuMG cells underwent EMT w/ the IIIc-isoform of FGFR1[17]. After NMuMG cells pretreated w/ TGF-beta transfected w/ mouse Fgfr1 siRNA or treated w/ SU5402, the cells further incubated in culture medium (CM) from TSU cells. SU, SU5402; siFR1, siRNA against mouse Fgfr1. (D)FGF2 mRNA levels determined by RT-qPCR analyses. The ratio of FGF2 mRNA to GAPDH mRNA in HSC-4 cells indicated as “1”. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained in at least three independent experiments. (E) ERK1/2 phosphorylation (p-ERK1/2) in TSU & HOC313 cells monitored in presence of indicated concentration of SU5402 for 1 h under serum-free culture conditions, followed by immunoblot analysis. (F, G) Expression of indicated genes in TSU cells under serum-free culture conditions determined by RT-qPCR (F) & immunoblot (G) analyses, following treatment w/ 10 μM SU5402. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained from at least three independent experiments. p values determined by Student’s t-test. **p < 0.01. (H) TSU cells treated w/ 10 μM U0126 in absence of FBS subjected to immunoblotting w/ the indicated antibodies. alpha -tubulin used as a loading control (A, B, C, E, G, & H). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616017.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - SU5402, FGFR1 inhibitor, affects the EMT transcription factors.(A, B) ERK1/2 phosphorylation (p-ERK1/2) determined by immunoblotting in HSC-4 & OTC-04 treated for 30 min w/ 30 ng/ml FGF2 or 30 ng/ml FGF7 in presence of 10% FBS (A) & in TSU & HOC313 cells treated for 1 h w/ 30 ng/ml FGF2 or 30 μM SU5402 in absence of FBS (B). F2, FGF2; F7, FGF7; SU, SU5402. (C) We have previously reported that, after treatment w/ TGF-beta , NMuMG cells underwent EMT w/ the IIIc-isoform of FGFR1[17]. After NMuMG cells pretreated w/ TGF-beta transfected w/ mouse Fgfr1 siRNA or treated w/ SU5402, the cells further incubated in culture medium (CM) from TSU cells. SU, SU5402; siFR1, siRNA against mouse Fgfr1. (D)FGF2 mRNA levels determined by RT-qPCR analyses. The ratio of FGF2 mRNA to GAPDH mRNA in HSC-4 cells indicated as “1”. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained in at least three independent experiments. (E) ERK1/2 phosphorylation (p-ERK1/2) in TSU & HOC313 cells monitored in presence of indicated concentration of SU5402 for 1 h under serum-free culture conditions, followed by immunoblot analysis. (F, G) Expression of indicated genes in TSU cells under serum-free culture conditions determined by RT-qPCR (F) & immunoblot (G) analyses, following treatment w/ 10 μM SU5402. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained from at least three independent experiments. p values determined by Student’s t-test. **p < 0.01. (H) TSU cells treated w/ 10 μM U0126 in absence of FBS subjected to immunoblotting w/ the indicated antibodies. alpha -tubulin used as a loading control (A, B, C, E, G, & H). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616067.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Vimentin & ZEB1 protein levels are regulated by OVOL1 & OVOL2 in a human SCC cell line. (A) Relative protein expression levels of OVOL1 & OVOL2 in A431 cells treated with control siRNA, OVOL1 siRNA, or OVOL2 siRNA for 48 h. (Left) Representative blot images & (right) relative expression levels calculated from three independent experiments. (B) Relative protein expression levels of vimentin, ZEB1, & E-cadherin in A431 cells treated with control siRNA, OVOL1 siRNA, or OVOL2 siRNA for 72 h. (Upper) representative blot images & (lower) relative protein expression levels calculated from three independent experiments. Mann–Whitney U-test; error bars represent mean ± standard deviation. Protein expressions are relative to those of beta -actin as a reference. The control siRNA value was set to 1. p-values < 0.05 were assumed to indicate a statistically significant difference; * p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32106476), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416175281.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - PDGFR-alpha / beta promotes sarcoma CSC migration/invasion & anchorage-independent growth.a Western blot analysis of cell adhesion protein N-cadherin & EMT transcription factors Snail, Slug, & Zeb1 in human sarcoma cell lines grown as monolayers & as spheroids. beta -actin was used as the loading control. b Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids for 24–48 h. Graphs display the number of migrated or invasive cells per field. c Representative light microscopy images of forrmed colonies in soft agar assay of human sarcoma cell lines grown as monolayers or spheroids for 14–20 days. Graph displays the number colonies per field. d Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids. Spheroid cells were treated with imatinib or DMSO. e Western blot analysis of N-cadherin & EMT-regulating transcription factors in human sarcoma cell lines grown as spheroids & treated with imatinib or DMSO. Experiments in a & e were performed three times with similar results. Bars represent standard deviation. *p < 0.05 compared to Monolayers Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-018-0059-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416182642.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - FGFR1 siRNAs attenuate the malignant phenotypes of cancer cells.(A) mRNA from TSU cells transfected with siRNAs against FGFR1 (siFGFR1) were subjected to conventional RT-PCR to determine the levels of endogenous FGFR1. (B, C, D) After transfection with siFGFR1 in TSU cells, phosphorylation of ERK1/2 (p-ERK1/2) (B), ZEB1 levels (C), & cell morphology (D) were determined. (E) TSU cells transfected with siFGFR1 were subjected to immunofluorescence analyses. Low magnification, 40×; high magnification, 80×. (F, G, H, I) After either treatment with SU5402 or transfection with siFGFR1 in TSU & HOC313 cells, the number of cells & invasive properties were determined under serum-free culture conditions. (J & K) After transfection with siFGFR1c in TSU & HOC313 cells, invasive & migratory properties were determined under serum-free culture conditions in TSU & HOC313 cells, respectively. siNC, non-specific control siRNA. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results were obtained from at least three independent experiments. p values were determined by Student’s t-test. *p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416175241.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - PDGFR-alpha / beta promotes sarcoma CSC migration/invasion & anchorage-independent growth.a Western blot analysis of cell adhesion protein N-cadherin & EMT transcription factors Snail, Slug, & Zeb1 in human sarcoma cell lines grown as monolayers & as spheroids. beta -actin was used as the loading control. b Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids for 24–48 h. Graphs display the number of migrated or invasive cells per field. c Representative light microscopy images of forrmed colonies in soft agar assay of human sarcoma cell lines grown as monolayers or spheroids for 14–20 days. Graph displays the number colonies per field. d Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids. Spheroid cells were treated with imatinib or DMSO. e Western blot analysis of N-cadherin & EMT-regulating transcription factors in human sarcoma cell lines grown as spheroids & treated with imatinib or DMSO. Experiments in a & e were performed three times with similar results. Bars represent standard deviation. *p < 0.05 compared to Monolayers Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-018-0059-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416163718.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Nav1.4 protein levels are decreased in muscles from mouse models of SMA. (A) Immunoblot analysis using muscle lysate from P2, P5, P9, & P21 wild type mice. Nav1.4 protein levels increase during postnatal muscle development & form the predominant sodium channel expressed in mature skeletal muscle. GAPDH served as a loading control (N = 3). (B) Representative immunoblot with quantification, showing a decrease in levels of sodium channel Nav1.4 & Nav1.5 in P5 Smn-/-;SMN2 hindlimb muscle compared with controls (N = 3). (C) Quantification of immunoblot analyses in P21 Smn2B/- & control hindlimb muscles revealed a decrease in Nav1.4 levels. Early in postnatal muscle development, the Nav1.5 sodium channel isoform is the most predominant. In P21 Smn2B/- mice, the protein levels of Nav1.5 are higher than in controls (N = 3). (D) The protein level of the Nav1.4 positive regulator, NF1, is not altered in muscles from P21 Smn2B/- mice. Similarly, no change was detected in the protein levels of the Nav1.4 repressor ZEB. (E) Expression of sodium channel Nav1.4 in control sham & denervated samples 1 & 7 days post-denervation was assessed by immunoblot (N = 3). A decrease in the levels of Nav1.4 in muscle was noted at 7 days post-denervation. *, P < 0.05; **, P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24119341), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241617522.jpg)
![Simple Western: beta-Actin Antibody [NB600-532] - Simple Western lane view shows a specific band for Beta Actin using NB600-532 at 1:200 in A431, C2C12 and C6 cell lysates. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Simple-Western-NB600-532-img0016.jpg "Simple Western: beta-Actin Antibody [NB600-532] - Simple Western lane view shows a specific band for Beta Actin using NB600-532 at 1:200 in A431, C2C12 and C6 cell lysates. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Western Blot: beta-Actin Antibody [NB600-532] - Detection of actin in 3T3 lysates (20ug). ECL detection 30 seconds. A specific band is seen using different dilutions: Lane 1 (1:15,000), Lane 2 (1:10,000), and Lane 3 (1:15,000).](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0009.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Detection of human and mouse Cytoskeletal Actin by western blot. Samples: Whole cell lysate (50 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Cytoskeletal Actin antibody NB600-532 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0014.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Mouse colon whole cell lysate. PVDF membrane was probed with Rabbit Anti-B actin Antibody (Catalog # NB600-532) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0019.jpg)
![Immunohistochemistry: beta-Actin Antibody [NB600-532] - Detection of human Cytoskeletal Actin by immunohistochemistry. Sample: FFPE section of human ovarian cancer. Antibody: Affinity purified rabbit anti-Cytoskeletal Actin (NB600-532). Detection: DAB](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Immunohistochemistry-NB600-532-img0015.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Western blot analysis of Actin (NB600-532) using RCC4 whole cell lysate [NBP1-30412].](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0006.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Western blot analysis of Actin (NB600-532) using HepG2 whole cell lysate [NBP1-42569].](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0007.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Analysis using the HRP conjugate of NB600-532. Detection of Beta Actin in MCF-7 cell lysate (20ug) using anti-Beta Actin antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0011.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Treatments of periplocin and/or TRAIL activate DR4, FADD, and proapoptotic proteins in HCC cells. The effect of periplocin treatment on the expression of DR4, DR5, and FADD was analyzed by western blot. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ecam/2013/958025/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0018.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Hypoxic preconditioning increases PBMNC sensitivity to apelin-13 via upregulation of APJ expression, leading to growth factor secretion.(a) APJ protein expression was significantly increased in hypoxic PBMNCs. *p <0.05 vs. N-PBMNCs. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep19379), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0017.jpg)
![Immunohistochemistry: beta-Actin Antibody [NB600-532] - Sample: FFPE section of human lung carcinoma. Antibody: Affinity purified rabbit anti-Cytoskeletal Actin used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Immunohistochemistry-NB600-532-img0012.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Cotreatment of periplocin & TRAIL activated IAP. (a) The expression levels of Bax, Bad, Mcl-1, apaf-1, & caspase 9 in HA22T/VGH in response to 1 μM periplocin and/or 100 ng/mL TRAIL treatment were examined by western blot. (b) The expression levels of Bcl-2, cIAP-1, cIAP-2, XIAP, & survivin in HA22T/VGH in response to 1 μM periplocin and/or 100 ng/mL TRAIL treatment were examined by western blot. The original blots are shown in supplemental Figure 2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23365613), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-310202415284538.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Treatments of periplocin and/or TRAIL activate DR4, FADD, & proapoptotic proteins in HCC cells. (a) The effect of periplocin treatment on the expression of DR4, DR5, & FADD was analyzed by western blot. (b) HA22T/VGH cells were treated with different doses of the indicated compounds for 24 h. Expressions of both proforms & cleaved forms of caspase-8, caspase 3, PARP, & BID were analyzed by western blotting. (c) Huh-7 cells were treated with different concentrations of the indicated compounds for 4 h or 24 h. The expression of caspase-8, caspase-9 was analyzed after indicated compounds treatment for 4 h, & the expression of caspase 3, PARP, BID was analyzed after the treatment of indicated compounds for 24 h. (d) HA22T/VGH cells were pretreated with 20 μM or 50 μM inhibitors against caspase-3 (Z-DEVD-FMK), caspasae-8 (Z-IETD-FMK), caspase-9 (Z-LEHD-FMK), & general caspase inhibitor (Z-VAD-FMK) for 3 hours prior to periplocin and/or TRAIL treatment. Cell viability was examined by MTT assay. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23365613), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-310202416182625.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - GRN PTC readthrough rescues FTLD/NCL lysosomal pathological CSTD maturation phenotype in hiPSC-derived R493X−/− KI cortical neurons. a DIV 80 WT & R493X−/− KI hiPSC-derived cortical neurons were treated with vehicle solution, G418 alone, G418 in combination with CDX5–288, & rec. Human PGRN at the indicated concentrations for 72 h. Expression of mature CSTD in treated WT & R493X−/− KI cortical neuron lysates analyzed by western blotting, using actin as the loading control. b Densitometric quantification of CSTD expression in the aforementioned cortical neuron lysates normalized to vehicle-treated WT levels. n = 3–6 independent cultures; values are shown as mean ± SEM; * p < 0.05, ** p < 0.01, was determined by one-way ANOVA with Tukey’s multiple comparison test Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32178712), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-31020241618923.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Induction of PTC readthrough by G418 & enhancers in hiPSC-derived R493X−/− KI astrocytes. a R493X−/− KI hiPSC-derived astrocytes were treated with vehicle solution, G418 alone, G418 in combination with CDX5–288, & rec. Human PGRN at the indicated concentrations for 72 h. Expression of PGRN & GRN-2,3 peptides in treated WT & R493X−/− KI astrocyte samples were analyzed by western blotting, using actin as the loading control. b Densitometric quantification of ~ 70 kDa PGRN (i) & GRN-2,3 peptide (ii) in astrocyte lysates (a) normalized to vehicle-treated (VT) WT levels. VT WT was excluded from ii due to oversaturation of GRN-2,3 signal in long exposure blot. For clarity, rec. Human PGRN treated R493X−/− KI astrocytes expressed 20.9% ± 0.027 of VT WT GRN-2,3 levels based on quantification of the short exposure blot (data not shown). c R493X−/− KI hiPSC-derived astrocytes were treated with vehicle solution, G418 in combination with CDX5–288, & G418 CDX5–288 combination with either 10 or 30 μM of Z-Phe-Phe-FMK for 72 h. Again, expression of PGRN in WT & R493X−/− KI astrocyte lysates was also analyzed by western blotting, using actin as the loading control. d Densitometric quantification of full-length PGRN in astrocyte lysates (c) normalized to VT WT levels. n = 3 independent cultures (except in dn = 2); values are shown as mean ± SEM; p < 0.05, ** p < 0.01, *** p < 0.0001 was determined by one-way ANOVA with Tukey’s multiple comparison test Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32178712), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-310202416163749.jpg)
![Simple Western: beta-Actin Antibody [NB600-532] - Induction of PTC readthrough by G418 & CDX5 enhancers in cells expressing GRN-V5. a Schematic of full-length PGRN highlighting the position of the S116X (UAA), R418X (UGA), & R493X (UGA) nonsense mutations in relation to the position of individual granulin peptides & the C-terminal V5 tag. b HEK293 cell lines stably expressing GRN-V5 with the indicated nonsense mutations were treated with G418 & the indicated concentrations of CDX5–1, CDX5–196, & CDX5–288 for 72 h. Cell culture supernatants (extracellular) & cell lysates (intracellular) were subjected to automated capillary electrophoresis western analysis. Full-length PGRN was detected with a V5 antibody. Actin was measured in cell lysates as a loading control. The readthrough enhancement ratios are indicated under the lanes. The proportion loaded was 15–20 fold lower for the extracellular samples than for the intracellular samples Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32178712), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-310202416173532.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0012.jpg "Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Mouse J774A.1, mouse reticulum cell sarcoma macrophage cell line. Left panel is + Anti-Rabbit FITC; middle panel indicates the cell nuclei stained with Hoechst; the right panel is a merged image. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0008.jpg)
![Immunohistochemistry-Paraffin: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - SPM receptors differentially expressed on endothelium and infiltrating leukocytes AE](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NLS1878-img0011.jpg)
![Flow Cytometry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Flow Cytometry: [Alexa Fluor® 700] [NLS1878AF700] - Mouse splenocytes. Cells were pre-gated with live/dead and FSC-A/W to exclude dead cells and cell doublets. Image from verified customer review. Image using the Alexa Fluor 700 form of this antibody.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Flow-Cytometry-NLS1878-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Murine neutrophils were extracted from the bone marrow of C57BL/6 mice and exposed to normal glucose (90 mg/dl) or high glucose (300 mg/dl) and the expression of FPR2 was assessed by western blotting after 1, 2, or 3 hr exposure to glucose. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35112667/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2 Antibody - BSA Free-Western Blot-NLS1878-img0013.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in HL-60 cell lysate.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Antibody was tested in Raw264.7 cells with DyLight 488 (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0005.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in human kidney cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-NLS1878-img0006.jpg)
![Electron Microscopy: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c=50A nm, e=100A nm. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Electron-Microscopy-NLS1878-img0010.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382420.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534335.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534380.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382435.jpg)
![Immunocytochemistry/ Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Lipoxin A4, along with its precursors & ligand, were altered by hAECs. (A): Expression of the lipoxin A4 precursor genes ALOX‐5, ‐12, & ‐15 was increased at days 5 & 7 compared with saline controls (ALOX‐5: 0.393 ± 0.114 vs. 3.777 ± 1.98; ALOX‐12: 0.484 ± 0.248 vs. 1.520 ± 0.203; ALOX‐15: 0.020 ± 0.007 vs. 1.998 ± 0.983). ∗, p < .05. (B): Lipoxin A4 protein levels were elevated in lung lysates at day 7 in animals treated with hAECs compared with controls (0.103 ± 0.021 ng/ml vs. 0.249 ± 0.072 ng/ml, respectively). ∗, p < .05. (C): At day 7, bleomycin challenge resulted in positively stained F4/80/FPR2 cells, which were was elevated in mice treated with hAECs compared with control mice (5.720% ± 0.587% vs. 8.795% ± 0.687%, respectively). ∗, p < .05. (D): Representative images of F4/80‐ & FPR2‐positive‐stained lung sections from hAEC‐treated animals. Magnification: ×200. Scale bar =100 μm. Abbreviations: DAPI, 4′,6‐diamidino‐2‐phenylindole; FPR2, N‐formyl peptide receptor 2; hAEC, human amnion epithelial cell. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28371562), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202416114742.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Higher expression of Fpr2 in the livers of female mice is related with hepatocyte protection.a qRT-PCP analysis for Fpr2 expression in primary hepatocytes (pHEPs) from WT (male n = 2, female n = 2) & KO mice (male n = 2, female n = 2). Total eight mice were employed in each hepatocyte isolation, & the experiments were replicated at least three times & the mean ± S.E.M. results are graphed (*p < 0.05, **p < 0.005 vs WT male-pHEPs). b Western blot analysis & c double immunofluorescent images of Fpr2 (red) with albumin (green) in these cells. Gapdh was used as internal control. DAPI (blue) was used as nuclear counterstaining. Data shown represent one of three experiments with similar results (Scale bar, 20 μm). d qRT-PCR analysis for Fpr2 & glucose-6-phosphatase (G6pc) in, e cell viability of, & f western blot analysis of cleaved Caspase-3 & pro Caspase-3 in WT & KO female mice-isolated pHEPs treated with vehicle (Veh) or 250 μM of palmitate (PA). The data shown represent one of three experiments with similar results. The mean ± S.E.M. results obtained from three repetitive experiments are graphed (*p < 0.05, **p < 0.005 vs WT-Veh). Gray circles represent individual data points. See Supplementary Data for statistical details. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35102146), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-3102024161228.jpg)
![Immunohistochemistry-Paraffin: PML Protein Antibody [NB100-59787] - IHC analysis of a formalin fixed and paraffin embedded tissue section of human stomach using 1:50 dilution of PML antibody. The signal was developed using HRP-labeled secondary with DAB reagent followed by hematoxylin counterstaining. This antibody generated an expected strong nuclear staining in most of the cells in the glandular as well as the connective tissue. The cells showed some cytoplasmic signal also which was much weaker than the nuclear staining.](http://images.novusbio.com/fullsize/PML-Protein-Antibody-Immunohistochemistry-Paraffin-NB100-59787-img0018.jpg "Immunohistochemistry-Paraffin: PML Protein Antibody [NB100-59787] - IHC analysis of a formalin fixed and paraffin embedded tissue section of human stomach using 1:50 dilution of PML antibody. The signal was developed using HRP-labeled secondary with DAB reagent followed by hematoxylin counterstaining. This antibody generated an expected strong nuclear staining in most of the cells in the glandular as well as the connective tissue. The cells showed some cytoplasmic signal also which was much weaker than the nuclear staining.")
![Immunohistochemistry: PML Protein Antibody [NB100-59787] - Sample: FFPE section of human prostate carcinoma. Antibody: Affinity purified rabbit anti- PML used at a dilution of 1:1,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/PML-Protein-Antibody-Immunohistochemistry-NB100-59787-img0017.jpg)
![Western Blot: PML Protein Antibody [NB100-59787] - Detection of Human PML on HeLa whole cell lysate using NB100-59787. PML was also immunoprecipitated by rabbit anti-PML antibodies NB100-59788 and another CDC16/APC6 Ab.](http://images.novusbio.com/fullsize/PML-Protein-Antibody-Western-Blot-NB100-59787-img0016.jpg)
![Western Blot: PML Protein Antibody [NB100-59787] - PML-RARa is a HIF-I+-transcriptional co-activator. HEK-293 cells transfected with stable mutants of HIF-1I+-or HIF-2I+-and increasing concentrations of PML-RARI+-. Image collected and cropped by Citeab from the following publication (HIF factors cooperate with PML-RAR +/- to promote acute promyelocytic leukemia progression and relapse. EMBO Mol Med (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PML-Protein-Antibody-Western-Blot-NB100-59787-img0019.jpg)
![Immunocytochemistry/Immunofluorescence: PML Protein Antibody - BSA Free [NB100-59787] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with PML Protein Antibody (NB100-59787) at 2ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/PML-Protein-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-59787-img0021.jpg)
![Immunocytochemistry/Immunofluorescence: PML Protein Antibody - BSA Free [NB100-59787] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with PML Protein Antibody (NB100-59787) at 1ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PML-Protein-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-59787-img0020.jpg)
![Immunohistochemistry-Paraffin: PML Protein Antibody [NB100-59787] - FFPE section of human breast carcinoma. Affinity purified rabbit anti-PML used at a dilution of 1:500](http://images.novusbio.com/fullsize/PML-Protein-Antibody-Immunohistochemistry-Paraffin-NB100-59787-img0015.jpg)
![Proximity Ligation Assay: PML Protein Antibody [NB100-59787] - Secondary-conjugate Duolink II PLA in Hela cells. goat anti-human SMARCA4 (NBP2-22234) and rabbit anti-human PML (NB100-59787). Image merged from DAPI (2ms) and Texas Red (200ms) exposures, 40X magnification.](http://images.novusbio.com/fullsize/PML-Protein-Antibody-Proximity-Ligation-Assay-NB100-59787-img0006.jpg)
![Proximity Ligation Assay: PML Protein Antibody [NB100-59787] - Secondary-conjugate Duolink II PLA in Hela cells. goat anti-human RFC4 (NB100-233) and rabbit anti-human PML (NB100-59787). Image merged from DAPI (2ms) and Texas Red (200ms) exposures, 40X magnification.](http://images.novusbio.com/fullsize/PML-Protein-Antibody-Proximity-Ligation-Assay-NB100-59787-img0014.jpg)
![Western Blot: PML Protein Antibody - BSA Free [NB100-59787] - PML-RARa is a HIF-alpha transcriptional co-activator.A HIF-alpha transactivation assays (A–D) with HRE-luciferase construct. Results are presented as Luciferase/Renilla ratio (mean ± s.e.m. of experiments performed in triplicate).B HEK-293 cells transfected with stable mutants of HIF-1 alpha or HIF-2 alpha & increasing concentrations of PML-RAR alpha .C HEK-293 cells transfected with a stable form of HIF-1 alpha along with PML-RAR alpha , PML or RAR alpha .D Wild-type & Pml−/− MEFs transfected with HIF-1 alpha & PML-RAR alpha . Asterisks indicate fold change induction of HIF-1 alpha -mediated transactivation upon PML-RAR alpha expression.E HEK-293 cells transfected with the indicated fusion genes & treated with CoCl2.F Co-immunoprecipitation of exogenous stable forms of HIF-1 alpha (left panel) & HIF-2 alpha (right panel) & PML-RAR alpha with a PML-directed antibody in HEK-293 cells. Of note, exogenously expressed PML-RAR alpha migrates very closely to endogenous PML.Co-immunoprecipitation of endogenous HIF-1 alpha & PML-RAR alpha with a PML-directed antibody in NB4 cells treated with CoCl2.Data information: All experiments were repeated at least twice.Source data are available for this figure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24711541), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-59787_rabbit-pml-protein-pab-bsa-free-3102024168217.jpg)
![Western Blot: RPA2 [p Ser4, p Ser8] Antibody [NBP1-23017] - Detection of Human Phospho RPA32 (S4/S8) by western blot. Samples: Whole cell lysate (50 ug) from HeLa cells treated with 100 uM EPE (+) or mock treated (-). Antibodies: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) antibody NBP1-23017 used at 0.1 ug/ml. Lower panel: Rabbit anti-RPA32 antibody NB100-332. Detection: Chemiluminescence with an exposure time of 75 seconds.](http://images.novusbio.com/fullsize/RPA2-[p-Ser4--p-Ser8]-Antibody-Western-Blot-NBP1-23017-img0047.jpg "Western Blot: RPA2 [p Ser4, p Ser8] Antibody [NBP1-23017] - Detection of Human Phospho RPA32 (S4/S8) by western blot. Samples: Whole cell lysate (50 ug) from HeLa cells treated with 100 uM EPE (+) or mock treated (-). Antibodies: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) antibody NBP1-23017 used at 0.1 ug/ml. Lower panel: Rabbit anti-RPA32 antibody NB100-332. Detection: Chemiluminescence with an exposure time of 75 seconds.")
![Immunocytochemistry/Immunofluorescence: RPA2 [p Ser4, p Ser8] Antibody [NBP1-23017] - Formaldehyde-fixed asynchronous HeLa cells. Untreated cells (left) and EPE treated cells (right). Antibody: Affinity purified rabbit anti- Phospho RPA32 (S4/S8) used at a dilution of 1:1,000 (1ug/ml). Detection: Red-fluorescent goat anti-rabbit IgG-heavy and light chain cross-adsorbed Antibody DyLight® 594 Conjugated used at a dilution of 1:100. Counterstain: Alexa Fluor (R) 488 phalloidin (green).](http://images.novusbio.com/fullsize/RPA2-[p-Ser4--p-Ser8]-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-23017-img0046.jpg)
![Immunohistochemistry-Paraffin: RPA2 [p Ser4, p Ser8] Antibody [NBP1-23017] - Section of mouse gut, MOCK treatment (left) and CIP treatment (right).Antibody: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/RPA2-[p-Ser4--p-Ser8]-Antibody-Immunohistochemistry-Paraffin-NBP1-23017-img0050.jpg)
![Western Blot: RPA2 [p Ser4, p Ser8] Antibody [NBP1-23017] - Samples: Whole cell lysate (50 ug for WB in A; 1 mg for IP, 20% of IP loaded in B) from HeLa Cells that had been treated with EPE (+) or mock treated (-). In B, immunoprecipitated RPA32 was either treated with phosphatase (+) or mock treated (-). Antibodies: Phosphorylated RPA32 was detected using rabbit anti-phospho RPA32 Ser4/Ser8 antibody NBP1-23017 lot 2 at 1 ug/ml. Total RPA32 was detected using rabbit anti-RPA32 antibody NB100-332 at 1 ug/ml. RPA32 was immunoprecipitated using NB100-332 at 3 ug/mg lysate. Detection: Chemiluminescence with exposure times of 30 seconds for phospho RPA32 Ser4/Ser8 (A and B) and 1 second for total RPA32 (A and B).](http://images.novusbio.com/fullsize/RPA2-[p-Ser4--p-Ser8]-Antibody-Western-Blot-NBP1-23017-img0003.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: RPA2 [p Ser4, p Ser8] Antibody [NBP1-23017] - Detection of Human Phospho RPA32 (S4/S8) by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa cells treated with 100 uM EPE for 4 hours (+) or mock treated (-) cells. Antibodies: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) antibody NBP1-23017 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds. Lower panel shows Westen Blot for total RPA32 using affinity purified rabbit anti-RPA32 antibody A300-244A at 0.1 ug/ml with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/RPA2-[p-Ser4--p-Ser8]-Antibody-Western-Blot-NBP1-23017-img0042.jpg)
![Immunohistochemistry-Paraffin: RPA2 [p Ser4, p Ser8] Antibody [NBP1-23017] - Section of human breast carcinoma, MOCK treatment (left) and CIP treatment(right). Antibody: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) (used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/RPA2-[p-Ser4--p-Ser8]-Antibody-Immunohistochemistry-Paraffin-NBP1-23017-img0049.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: RPA2 [p Ser4, p Ser8] Antibody [NBP1-23017] - Detection of human Phospho RPA32 (S4/S8) by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells treated with EPE (+) and/or Lambda PP (+) or mock treated (-). Antibodies: RPA32 (S4/S8) was immunoprecipitated using affinity purified rabbit anti-RPA32 antibody NB100-332. For blotting immunoprecipitated Phospho RPA32 (S4/S8), rabbit anti-Phospho RPA32 (S4/S8) antibody NBP1-23017 was used at 0.1 ug/ml. Lower Panel: Rabbit anti-RPA antibody NB100-332. Detection: Chemiluminescence with an exposure time of 75 seconds.](http://images.novusbio.com/fullsize/RPA2-[p-Ser4--p-Ser8]-Antibody-Immunoprecipitation-NBP1-23017-img0048.jpg)
![Western Blot: DDX6 Antibody [NB200-191] - Western blot analysis of LBCs show increased Staufen (STAU1) (NBP1-33202) levels compared with normal controls. DDX6 (NB200-191) levels are unchanged. HD and SCA3 patient (polyQ expanded) FBs were used as additional controls. Four normal and five SCA2 FBs, and two normal and three SCA2 LBCs were used.Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30194296/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DDX6-Antibody-Western-Blot-NB200-191-img0014.jpg "Western Blot: DDX6 Antibody [NB200-191] - Western blot analysis of LBCs show increased Staufen (STAU1) (NBP1-33202) levels compared with normal controls. DDX6 (NB200-191) levels are unchanged. HD and SCA3 patient (polyQ expanded) FBs were used as additional controls. Four normal and five SCA2 FBs, and two normal and three SCA2 LBCs were used.Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30194296/) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: DDX6 Antibody [NB200-191] - In normal condition, cells were fixed and stained for DDX6, that usually punctuate in process bodies (PBs). Primary Antibody rabbit-anti-DDX6 diluted 1:1000. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunocytochemistry-Immunofluorescence-NB200-191-img0008.jpg)
![Immunohistochemistry-Paraffin: DDX6 Antibody [NB200-191] - Section of human colon carcinoma (left) and mouse renal cell carcinoma(right). Antibody: Affinity purified rabbit anti-DDX6 used at a dilution of 1:200 (1ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunohistochemistry-Paraffin-NB200-191-img0013.jpg)
![Immunoprecipitation: DDX6 Antibody [NB200-191] - Detection of human DDX6 by Western Blot and Immunoprecipitation. Samples: Whole cell lysate (15 and 50 ug) from HeLa cells. Antibodies: Affinity purified rabbit anti-DDX6 antibody NB200-191 used at 0.04 ug/ml for WB (A and B) and at 3 ug/mg lysate for IP. DDX6 was also immunoprecipitated using rabbit anti-DDX6 antibody NB200-192, but not with 'DDX6 Ab', which is to another epitope from DDX6. Normal rabbit IgG was used as a negative control. Detection: Chemiluminescence with an exposure time of 1 second (A & B).](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunoprecipitation-NB200-191-img0012.jpg)
![Western Blot: DDX6 Antibody [NB200-191] - Staufen1 protein but not mRNA steady-state levels are increased in neurodegenerative disease cells & tissues. Western blot analysis of SCA2- FBs (a) & LBCs (b) show increased STAU1 levels compared with normal controls. DDX6 levels are unchanged. HD & SCA3 patient (polyQ expanded) FBs were used as additional controls. Four normal & five SCA2 FBs, & two normal & three SCA2 LBCs were used. c, d Western blot analyses of ATXN2Q127 (c) & BAC-Q72 (d) mouse cerebellar extracts (24 weeks of age) showing increased Stau1 levels compared with wild-type or BAC-Q22 controls (n = 2–3 animals per group). e Western blot of FB extracts from an ALS patient with the TDP-43G298S mutation show increased STAU1 levels. beta -Actin was used as loading control & representative blots of three independent experiments are shown. f–hSTAU1 RNA levels are unaltered in SCA2 & ALS cells & SCA2 mice. qRT-PCR analyses of STAU1 mRNA in SCA2 FBs & ALS FB with TDP-43G298S mutation (f) or SCA2 LBCs (g). h qRT-PCR analyses of cerebellar RNAs from ATXN2Q127 & BAC-Q72 mice compared to wild-type littermates (24 weeks of age; n = animals per group). Gene expression levels were normalized to Actb Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30194296), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-191_rabbit-polyclonal-ddx6-antibody-310202416212368.jpg)
![Western Blot: KAP1 [p Ser824] Antibody [NB100-2350] - MDA-MB-231 cells were treated with DMSO or Merbarone (100 uM) for 24 hours, whole cell lysates were loaded with 50 ug/lane. 10% SDS-PAGE. KAP1 [p Ser824] Antibody (NB100-2350) primary antibody at 1:1000, 4C, overnight. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/KAP1-[p-Ser824]-Antibody-Western-Blot-NB100-2350-img0019.jpg "Western Blot: KAP1 [p Ser824] Antibody [NB100-2350] - MDA-MB-231 cells were treated with DMSO or Merbarone (100 uM) for 24 hours, whole cell lysates were loaded with 50 ug/lane. 10% SDS-PAGE. KAP1 [p Ser824] Antibody (NB100-2350) primary antibody at 1:1000, 4C, overnight. Western blot image submitted by a verified customer review.")
![Immunocytochemistry/Immunofluorescence: KAP1 [p Ser824] Antibody [NB100-2350] - NBF-fixed asynchronous HeLa cells grown in chambered microscope slides and treated with EPE (left) or untreated (right). Antibody: Affinity purified rabbit anti-Phospho KAP-1 (S824) used at a dilution of 1:200 (1ug/ml). Detection: Red fluorescent Anti-rabbit IgG-DyLight (R) 594 conjugated used at a dilution of 1:100.](http://images.novusbio.com/fullsize/KAP1-[p-Ser824]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2350-img0015.jpg)
![Immunohistochemistry-Paraffin: KAP1 [p Ser824] Antibody [NB100-2350] - Human Phospho Kap1 (S824) by Immunohistochemistry. Sample: FFPE serial section of human lung cancer used at a dilution of 1:200 (1 ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/KAP1-[p-Ser824]-Antibody-Immunohistochemistry-Paraffin-NB100-2350-img0014.jpg)
![Western Blot: KAP1 [p Ser824] Antibody [NB100-2350] - Samples: Whole cell lysate (15 ug) from NIH 3T3 cellstreated with 100 uM etoposide (+) or mock treated (-).Antibodies: Affinity purified rabbit anti-Phospho KAP-1(S824) antibody used forWB at 0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 30 seconds. Lower panel shows westernblot for total KAP-1 using rabbit anti-KAP-1 recombinantmonoclonal antibody at 1:1000.](http://images.novusbio.com/fullsize/KAP1-[p-Ser824]-Antibody-Western-Blot-NB100-2350-img0017.jpg)
![Western Blot: KAP1 [p Ser824] Antibody [NB100-2350] - Samples: Whole cell lysate (50 ug) from HEK293Tcells treated with 100 uM etoposide (+) or mock treated(-). Antibodies: Affinity purified rabbit anti-Phospho KAP-1(S824) antibody used forWB at 0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 1 second. Lower panel shows westernblot for total KAP-1 using affinity purified rabbit anti KAP-1 antibody at 0.1 ug/ml.](http://images.novusbio.com/fullsize/KAP1-[p-Ser824]-Antibody-Western-Blot-NB100-2350-img0018.jpg)
![Immunohistochemistry-Paraffin: KAP1 [p Ser824] Antibody [NB100-2350] - FFPE serial sections of asynchronous HeLa cells treated with EPE (left) anduntreated HeLa cells (right). Antibody: Affinity purified rabbit anti-Phospho KAP-1 (S824) used at a dilution of 1:200 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/KAP1-[p-Ser824]-Antibody-Immunohistochemistry-Paraffin-NB100-2350-img0013.jpg)
![Immunoprecipitation: KAP1 [p Ser824] Antibody [NB100-2350] - Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from HEK293T cells treated with 100 uM etoposide (+) or mock treated (-). Antibodies: Rabbit anti-Phospho KAP-1 (S824) and rabbit anti-KAP-1 recombinant monoclonal antibody used for IP at 6 ug/mg lysate. For blotting immunoprecipitated Phospho KAP-1 (S824), Antibody was used at 0.04 ug/ml. To examine total KAP-1, the blot was stripped and then blotted with this antibody at 1:1000 (lower panel). Detection: Chemiluminescence with an exposure time of 1 second.Previous](http://images.novusbio.com/fullsize/KAP1-[p-Ser824]-Antibody-Immunoprecipitation-NB100-2350-img0016.jpg)
![Western Blot: KAP1 [p Ser824] Antibody [NB100-2350] - MAGE I regulates KAP1 gene binding, trimethylation of histone 3 on lysine 9, & gene repression in HEK293T cells.MAGE I expression decreases binding of KAP1, H3me3K9, & repression of the ID1 tumor suppressor gene (A, B, D). In contrast, MAGE I expression increases binding of KAP1, H3me3K9, & repression of mRNA & protein levels of the Ki67 gene (E, F, H, I, J, L). Note MAGE I binds to Ki67 gene sites but not ID1 gene sites (C, G, K). “M” denotes Mock transfection control. “A3” & “C2” denote MAGE-A3 & MAGE-C2, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21876767), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2350_rabbit-polyclonal-kap1-p-ser824-antibody-310202415334921.jpg)
![Western Blot: KAP1 [p Ser824] Antibody [NB100-2350] - Truncated PPM1D impairs DNA damage response in mouse thymus. Expression of PPM1D mRNA analyzed by RT-qPCR in thymi of Ppm1d+/+, Ppm1dT/+ & Ppm1dT/T mice & normalized to GAPDH (n = 3) (A). Thymi from mice of indicated genotypes lysed & proteins separated by SDS-PAGE. Samples probed w/ antibody against PPM1D & importin-beta as a loading control. The empty & full arrowheads indicate the position of full-length & the C-terminally truncated PPM1D, respectively. (B). Cells from thymi from Ppm1d+/+ & Ppm1dT/+ mice analyzed by flow cytometry. Plotted are the counts of indicated populations as follows: double-negative T-cells (DN & DN1, DN2, DN3, DN4), double-positive T-cells (DP), CD8-positive T-cells (CD8+) & CD4-positive T-cells (CD4+) (n = 3) (C). The median size of thymus determined in Ppm1d +/+ (n = 11) & Ppm1dT/+ (n = 12) mice (D). A scheme of experimental setup in F-I. Mice exposed or not to a low dose of IR (3 Gy), sacrificed after 6 h & thymi & lymph nodes collected (E). Proteins isolated from thymi from mice of indicated genotypes exposed to mock or to IR probed w/ indicated antibodies by immunoblotting (F). Proteins isolated from inguinal lymph nodes from mice of indicated genotypes exposed to mock or to IR probed w/ indicated antibodies by immunoblotting (G). RNA isolated from thymi from mice in E analyzed by RT-qPCR. Expression of CDKN1Ap21 mRNA normalized to GAPDH. Statistical significance evaluated by two-tailed t-test, error bars indicate SD, n = 5 (H). RNA isolated from thymi from mice in D analyzed by RT-qPCR. Expression of PUMA mRNA normalized to GAPDH. Statistical significance evaluated by two-tailed t-test, error bars indicate SD, n = 5. * p <0.05; *** p < 0.0005; **** p < 0.0001 (I). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32927737), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2350_rabbit-polyclonal-kap1-p-ser824-antibody-3102024161262.jpg)
![Western Blot: KAP1 [p Ser824] Antibody [NB100-2350] - Truncated PPM1D impairs DNA damage response in mouse thymus. Expression of PPM1D mRNA analyzed by RT-qPCR in thymi of Ppm1d+/+, Ppm1dT/+ & Ppm1dT/T mice & normalized to GAPDH (n = 3) (A). Thymi from mice of indicated genotypes lysed & proteins separated by SDS-PAGE. Samples probed w/ antibody against PPM1D & importin-beta as a loading control. The empty & full arrowheads indicate the position of full-length & the C-terminally truncated PPM1D, respectively. (B). Cells from thymi from Ppm1d+/+ & Ppm1dT/+ mice analyzed by flow cytometry. Plotted are the counts of indicated populations as follows: double-negative T-cells (DN & DN1, DN2, DN3, DN4), double-positive T-cells (DP), CD8-positive T-cells (CD8+) & CD4-positive T-cells (CD4+) (n = 3) (C). The median size of thymus determined in Ppm1d +/+ (n = 11) & Ppm1dT/+ (n = 12) mice (D). A scheme of experimental setup in F-I. Mice exposed or not to a low dose of IR (3 Gy), sacrificed after 6 h & thymi & lymph nodes collected (E). Proteins isolated from thymi from mice of indicated genotypes exposed to mock or to IR probed w/ indicated antibodies by immunoblotting (F). Proteins isolated from inguinal lymph nodes from mice of indicated genotypes exposed to mock or to IR probed w/ indicated antibodies by immunoblotting (G). RNA isolated from thymi from mice in E analyzed by RT-qPCR. Expression of CDKN1Ap21 mRNA normalized to GAPDH. Statistical significance evaluated by two-tailed t-test, error bars indicate SD, n = 5 (H). RNA isolated from thymi from mice in D analyzed by RT-qPCR. Expression of PUMA mRNA normalized to GAPDH. Statistical significance evaluated by two-tailed t-test, error bars indicate SD, n = 5. * p <0.05; *** p < 0.0005; **** p < 0.0001 (I). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32927737), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2350_rabbit-polyclonal-kap1-p-ser824-antibody-3102024155451.jpg)
![Western Blot: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds](http://images.novusbio.com/fullsize/USP7-Antibody-Western-Blot-NB100-513-img0004.jpg "Western Blot: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds")
![Immunohistochemistry-Paraffin: USP7 Antibody [NB100-513] - Sample: FFPE section of human ovarian carcinoma.Antibody: Affinity purified rabbit anti-USP7 used at 1:5,000 (0.2ug/ml). Detection:DAB](http://images.novusbio.com/fullsize/USP7-Antibody-Immunohistochemistry-Paraffin-NB100-513-img0002.jpg)
![Immunohistochemistry-Paraffin: USP7 Antibody [NB100-513] - Sample: FFPE section of mouse renal cell carcinoma.Antibody: Affinity purified rabbit anti-USP7 used at 1:5,000 (0.2ug/ml). Detection:DAB](http://images.novusbio.com/fullsize/USP7-Antibody-Immunohistochemistry-Paraffin-NB100-513-img0001.jpg)
![Immunoprecipitation: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds](http://images.novusbio.com/fullsize/USP7-Antibody-Immunoprecipitation-NB100-513-img0003.jpg)
![Western Blot: FUS Antibody [NB100-565] - Western blot shows lysates of HEK293 human embryonic kidney parental cell line and FUS knockout (KO) HEK293 human embryonic kidney cell line. PVDF membrane was probed with 1:1000 of Rabbit Anti-Human FUS Polyclonal Antibody (Catalog # NB100-565) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for FUS at approximately 75 kDa (as indicated) in the parental HEK293 celll line, but is not detectable in the knockout HEK293 cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/FUS-Antibody-Knockout-Validated-NB100-565-img0020.jpg "<b>Genetic Strategies Validation. </b>Western Blot: FUS Antibody [NB100-565] - Western blot shows lysates of HEK293 human embryonic kidney parental cell line and FUS knockout (KO) HEK293 human embryonic kidney cell line. PVDF membrane was probed with 1:1000 of Rabbit Anti-Human FUS Polyclonal Antibody (Catalog # NB100-565) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for FUS at approximately 75 kDa (as indicated) in the parental HEK293 celll line, but is not detectable in the knockout HEK293 cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: FUS Antibody [NB100-565] - FUS activates GSK-3beta in transfected cells and transgenic mice A. Cells were transfected with either control vector (CTRL), HA-FUS, HA-FUSR521C or HA FUSR518K and the samples probed on immunoblots for GSK-3beta phosphorylated on serine 9 (GSK-3beta-S9), total GSK-3beta, FUS (using FUS antibody) and tubulin as a loading control. Phosphorylation of GSK-3beta serine 9 is the principal mechanism for regulating its activity; serine 9 phosphorylation inhibits GSK-3beta activity. Bar chart shows relative levels of GSK-3beta serine 9 phosphorylation following quantification of signals from immunoblots and normalization to total GSK-3beta signals. Data were analysed by one-way ANOVA and Tukey's post hoc test. N = 4, error bars are s.e.m.; *P < 0.05. Image collected and cropped by CiteAb from the following publication (//onlinelibrary.wiley.com/doi/10.15252/embr.201541726), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FUS-Antibody-Western-Blot-NB100-565-img0023.jpg)
![Immunocytochemistry/Immunofluorescence: FUS Antibody [NB100-565] - FUS (NB100-565) (green), b-III Tubulin (white), DAPI (blue). FUS antibody dilution: 1:300 in PBST (0.1% Triton X-100) + 10% GS O/N 4C. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-565-img0022.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NB100-565] - FFPE section of mouse renal cells carcinoma. Affinity purified rabbit anti-FUS used at a dilution of 1:1,000 (1 ug/mL). Detection: DA](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NB100-565-img0017.jpg)
![Western Blot: FUS Antibody [NB100-565] - Whole cell lysate (50 ug) from HepG2, HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Affinity purified rabbit anti-FUS antibody used for WB at 0.04 ug/mL. Detection: chemiluminescence with an exposure time of 10 seconds.](http://images.novusbio.com/fullsize/FUS-Antibody-Western-Blot-NB100-565-img0019.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NB100-565] - FFPE section of human ovarian carcinoma. Affinity purified rabbit anti-FUS used at a dilution of 1:1,000 (1 ug/mL). Detection: DAB](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NB100-565-img0015.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: FUS Antibody [NB100-565] - Detection of human FUS by Western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-FUS antibody NB100-565 used for IP at 3 ug per reaction. FUS was also immunoprecipitated by rabbit anti-FUS recombinant monoclonal antibody [BLR023E] (NBP2-76415) and rabbit anti-FUS antibody NB100-561. For blotting immunoprecipitated FUS, NB100-565 was used at 1:1000. Detection: Chemiluminescence with an exposure time time of 3 minutes.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunoprecipitation-NB100-565-img0021.jpg)
![Immunocytochemistry/ Immunofluorescence: FUS Antibody [NB100-565] - hnRNP R & hnRNP Q form frequent inclusions in FTLD-FUS. Representative images of FUS, TRN1, hnRNP R & hnRNP Q immunohistochemical staining in the granule cell layer of the dentate fascia of the hippocampus in NIFID & aFTLD-U subtypes of FTLD-FUS. Single arrows indicate neuronal cytoplasmic inclusions & double arrows highlight intranuclear inclusions. Scale bars represent 50 μm in all images Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30755280), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241517520.jpg)
![Immunocytochemistry/ Immunofluorescence: FUS Antibody [NB100-565] - hnRNP R co-localises with FUS inclusions in NIFID & aFTLD-U cases. Representative images of double-label immunofluorescence in the cortex (a & b) & granular cell layer of the dentate gyrus (c & d) of a NIFID & aFTLD-U case demonstrating colocalisation of FUS (green) & hnRNP R (red) in neuronal cytoplasmic inclusions (white arrows) & intranuclear neuronal inclusions (white arrow heads). Neuronal nuclei are counterstained with DAPI. Scale bars represent 20 μm in all images Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30755280), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-310202415291990.jpg)
![Western Blot: FUS Antibody [NB100-565] - Expression of EGFP‐FUS reduces the expression of endogenous FUSHEK293 cells were transfected with control EGFP, EGFP‐FUS, EGFP‐FUSR521C or EGFP‐FUSR518K & 72 h post‐transfection, the samples were probed on immunoblots for FUS (using FUS antibody) & tubulin as a loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241539718.jpg)
![Western Blot: FUS Antibody [NB100-565] - FUS does not bind VAPB or PTPIP51 in immunoprecipitation assays from transfected HEK293 cellsCells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, myc‐VAPB + CTRL, or myc‐VAPB + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. VAPB was immunoprecipitated via the myc‐tag & the samples probed on immunoblots for VAPB using rabbit VAPB antibody & for co‐immunoprecipitating FUS via the HA tag. Input VAPB & FUS were detected using myc & HA antibodies.Cells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, HA‐PTPIP51 + CTRL or HA‐PTPIP51 + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. PTPIP51 was immunoprecipitated using rat anti‐PTPIP51 & the samples probed for PTPIP51 using rabbit anti‐HA antibody & for co‐immunoprecipitating FUS using rabbit FUS antibody. Input PTPIP51 & FUS were detected using PTPIP51 & EGFP antibodies, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241552395.jpg)
![Western Blot: FUS Antibody [NB100-565] - FUS does not bind VAPB or PTPIP51 in immunoprecipitation assays from transfected HEK293 cellsCells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, myc‐VAPB + CTRL, or myc‐VAPB + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. VAPB was immunoprecipitated via the myc‐tag & the samples probed on immunoblots for VAPB using rabbit VAPB antibody & for co‐immunoprecipitating FUS via the HA tag. Input VAPB & FUS were detected using myc & HA antibodies.Cells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, HA‐PTPIP51 + CTRL or HA‐PTPIP51 + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. PTPIP51 was immunoprecipitated using rat anti‐PTPIP51 & the samples probed for PTPIP51 using rabbit anti‐HA antibody & for co‐immunoprecipitating FUS using rabbit FUS antibody. Input PTPIP51 & FUS were detected using PTPIP51 & EGFP antibodies, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241612640.jpg)
![Western Blot: FUS Antibody [NB100-565] - FUS does not bind VAPB or PTPIP51 in immunoprecipitation assays from transfected HEK293 cellsCells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, myc‐VAPB + CTRL, or myc‐VAPB + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. VAPB was immunoprecipitated via the myc‐tag & the samples probed on immunoblots for VAPB using rabbit VAPB antibody & for co‐immunoprecipitating FUS via the HA tag. Input VAPB & FUS were detected using myc & HA antibodies.Cells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, HA‐PTPIP51 + CTRL or HA‐PTPIP51 + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. PTPIP51 was immunoprecipitated using rat anti‐PTPIP51 & the samples probed for PTPIP51 using rabbit anti‐HA antibody & for co‐immunoprecipitating FUS using rabbit FUS antibody. Input PTPIP51 & FUS were detected using PTPIP51 & EGFP antibodies, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-3102024168398.jpg)
![Western Blot: FUS Antibody [NB100-565] - Expression of wild‐type & ALS/FTD‐mutant FUS reduces ER–mitochondria associations in NSC34 cellsAExpression of FUS does not alter expression of VAPB, PTPIP51 or mitofusin‐2 (MFN2) in transfected NSC34 cells. Immunoblots of NSC34 cells transfected with EGFP as a control (CTRL), or wild‐type or mutant EGFP‐FUS. Transfected cells were purified via EGFP using a cell sorter & the samples probed on immunoblots as indicated. On the FUS immunoblot, samples were probed with FUS antibody to show endogenous & transfected proteins; tubulin is shown as a loading control.BRepresentative electron micrographs of ER–mitochondria associations in NSC34 cells transfected with control EGFP vector (CTRL), EGFP‐FUS, EGFP‐FUSR521C or EGFP‐FUSR518K as indicated; arrowheads with loops show regions of association. Scale bar = 200 nm. Bar chart shows % of the mitochondrial surface closely apposed to ER in the different samples. Data were analysed by one‐way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. N = 27–30 cells & 247–424 mitochondria, error bars are s.e.m.; ***P < 0.001.C, DsiRNA loss of FUS does not affect ER–mitochondria associations or alter expression of VAPB, PTPIP51 or mitofusin‐2 (MFN2) in NSC34 cells. (C) Immunoblots of cells either mock transfected or treated with control (CTRL) or FUS siRNAs; GAPDH is shown as a loading control. (D) Representative electron micrographs of ER–mitochondria associations in control (CTRL) & FUS siRNA‐treated cells. Arrowheads with loops show regions of association. Scale bar = 200 nm. Data analysed by unpaired t‐test. N = 27–28 cells & 193–202 mitochondria, error bars are s.e.m. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241682165.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - Detection of Human and Mouse DDX6 by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-DDX6 antibody NB200-192 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.](http://images.novusbio.com/fullsize/DDX6-Antibody-Western-Blot-NB200-192-img0009.jpg "Western Blot: DDX6 Antibody [NB200-192] - Detection of Human and Mouse DDX6 by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-DDX6 antibody NB200-192 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.")
![Immunohistochemistry-Paraffin: DDX6 Antibody [NB200-192] - FFPE section of human colon carcinoma. Antibody: Affinity purified rabbit anti-DDX6 (left) and Lot 3 (right) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB. Counterstain: IHC Hematoxylin (blue).](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunohistochemistry-Paraffin-NB200-192-img0008.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: DDX6 Antibody [NB200-192] - Detection of human DDX6 by western blot of immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-DDX6 antibody NB200-192 (lot NB200-192-3) used for IP at 6 ug per reaction. DDX6 was also immunoprecipitated by a previous lot of this antibody (NB200-192-2) and rabbit anti-DDX6 antibody NB200-191. For blotting immunoprecipitated DDX6, NB200-192 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunoprecipitation-NB200-192-img0010.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: DDX6 Antibody [NB200-192] - Western blot analysis of HNRNPK and DDX6 protein levels upon HNRNPK or DDX6 knockdown. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-019-12238-x), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DDX6-Antibody-Knockdown-Validated-NB200-192-img0011.jpg)
![Immunocytochemistry/ Immunofluorescence: DDX6 Antibody [NB200-192] - 5-FU-induced SG assembly is rescued by interfering with RNA incorporation. HeLa cells were treated with 1 mM Urd, 0.1 mM 5-FU or both, as well as with 1 μM FUrd or a combination of 1 μM FUrd & 10 μM Urd. Localization of SG marker protein TIAR (green) & SG/P-body marker protein DDX6 (red) was investigated. Nuclei were stained with Hoechst. Scale bars represent 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24728989), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202415363749.jpg)
![Immunocytochemistry/ Immunofluorescence: DDX6 Antibody [NB200-192] - 5-FU-induced SG assembly depends on RNA incorporation. (A) Schematic representation of the cellular 5-FU metabolism leading to incorporation of the different metabolites into RNA or DNA. (B) HeLa cells were treated with two concentrations of the 5-FU metabolites FUrd or FdUrd for 72 h. SG marker protein TIAR (green) & SG/P-body marker protein DDX6 (red) were visualized. Nuclei were stained with Hoechst. Scale bars represent 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24728989), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202415371964.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - HNRNPK is necessary for DDX6 to bind differentiation associated mRNAs. a RNA IP was performed in CTLi & HNRNPKi cells using a DDX6 antibody. RT-QPCR was used to determine the levels of binding between DDX6 & differentiation associated mRNAs in the presence or absence of HNRNPK. IGG IPs in CTLi & HNRNPKi cells were used as specificity controls. Binding was calculated as a percent of input. b RNA IP was performed in CTLi & DDX6i cells using a HNRNPK antibody. RT-QPCR was used to determine the levels of binding between HNRNPK & differentiation associated mRNAs in the presence or absence of DDX6. IGG IPs in CTLi & DDX6i cells were used as specificity controls. n = 4. c Western blot analysis of HNRNPK & DDX6 protein levels upon HNRNPK or DDX6 knockdown. d Immunoprecipitations (IPs) were performed using either an HNRNPK or DDX6 antibody or IGG & Western blotted for HNRNPK or DDX6 protein expression. IPs were performed +/− RNase A. Five percent of the cell lysate was used as input. Representative blots are shown. n = 3 independent experiments performed for Fig. 3 unless otherwise indicated. All error bars = SD. ****p < 0.0001, ***p < 0.001 (2 way ANOVA followed by Tukey’s multiple comparison test for a, b) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31519929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202416212349.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - HNRNPK is necessary for DDX6 to bind differentiation associated mRNAs. a RNA IP was performed in CTLi & HNRNPKi cells using a DDX6 antibody. RT-QPCR was used to determine the levels of binding between DDX6 & differentiation associated mRNAs in the presence or absence of HNRNPK. IGG IPs in CTLi & HNRNPKi cells were used as specificity controls. Binding was calculated as a percent of input. b RNA IP was performed in CTLi & DDX6i cells using a HNRNPK antibody. RT-QPCR was used to determine the levels of binding between HNRNPK & differentiation associated mRNAs in the presence or absence of DDX6. IGG IPs in CTLi & DDX6i cells were used as specificity controls. n = 4. c Western blot analysis of HNRNPK & DDX6 protein levels upon HNRNPK or DDX6 knockdown. d Immunoprecipitations (IPs) were performed using either an HNRNPK or DDX6 antibody or IGG & Western blotted for HNRNPK or DDX6 protein expression. IPs were performed +/− RNase A. Five percent of the cell lysate was used as input. Representative blots are shown. n = 3 independent experiments performed for Fig. 3 unless otherwise indicated. All error bars = SD. ****p < 0.0001, ***p < 0.001 (2 way ANOVA followed by Tukey’s multiple comparison test for a, b) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31519929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202416205119.jpg)